The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
Open accessAbstract
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Self-citationInborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229
Self-citationREGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Positional cloning of the APECED gene
Nagamine, K., Peterson, P., Scott, H. S., Kudoh, J., Minoshima, S., Heino, M., Krohn, K. J. E., Lalioti, M. D., Mullis, P. E., Antonarakis, S. E., et al. (1997) · Nature Genetics · doi:10.1038/ng1297-393 · Cited by 1,447
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Aaltonen, J., Björses, P., Perheentupa, J., Horelli–Kuitunen, N., Palotie, A., Peltonen, L., Lee, Y. S., Francis, F., Henning, S., Thiel, C., et al. (1997) · Nature Genetics · doi:10.1038/ng1297-399 · Cited by 1,228
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Ahonen, P., Myllärniemi, S., Sipilä, I., & Perheentupa, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222601 · Cited by 1,077
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056 · cited 1×
“Among these anti-cytokine auto-Abs, neutralizing auto-Abs against IL-17A and IL-17F phenocopy inborn errors of IL-17A/F and underlie chronicmucocutaneous candidiasis (CMC; Kisand et al., 2010; Puel et al., 2011; Puel et al., 2010).”
BackgroundSelf-citationDiverse functional autoantibodies in patients with COVID-19
Wang, E. Y., Mao, T., Klein, J., Dai, Y., Huck, J. D., Jaycox, J. R., Liu, F., Zhou, T., Israelow, B., Wong, P., et al. (2021) · Nature · doi:10.1038/s41586-021-03631-y · Cited by 992
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Simonovich, V. A., Burgos Pratx, L. D., Scibona, P., Beruto, M. V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sánchez, M. D. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031304 · Cited by 907
Puel, A., Döffinger, R., Natividad, A., Chrabieh, M., Barcenas-Morales, G., Picard, C., Cobat, A., Ouachée-Chardin, M., Toulon, A., Bustamante, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091983 · Cited by 733
Self-citationKisand, K., Bøe Wolff, A. S., Podkrajšek, K. T., Tserel, L., Link, M., Kisand, K. V., Ersvaer, E., Perheentupa, J., Erichsen, M. M., Bratanic, N., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091669 · Cited by 677
Self-citationIsaacs, A., & Lindenmann, J. (2015) · The Journal of Immunology · doi:10.1093/jimmunol/195.5.1911 · Cited by 602
Autoimmune Polyendocrine Syndromes
Husebye, E. S., Anderson, M. S., & Kämpe, O. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1713301 · Cited by 466
Self-citationAnti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1
Meager, A., Visvalingam, K., Peterson, P., Möll, K., Murumägi, A., Krohn, K., Eskelin, P., Perheentupa, J., Husebye, E., Kadota, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030289 · Cited by 453
Self-citationRice, G. I., Forte, G. M. A., Szynkiewicz, M., Chase, D. S., Aeby, A., Abdel-Hamid, M. S., Ackroyd, S., Allcock, R., Bailey, K. M., Balottin, U., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70258-8 · Cited by 443
Self-citationMonk, P. D., Marsden, R. J., Tear, V. J., Brookes, J., Batten, T. N., Mankowski, M., Gabbay, F. J., Davies, D. E., Holgate, S. T., Ho, L.-P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30511-7 · Cited by 438
Virus interference. II. Some properties of interferon
Isaacs, A., Lindenmann, J., & Valentine, R. C. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0049 · Cited by 413
Interferons and viruses: an evolutionary arms race of molecular interactions
Hoffmann, H.-H., Schneider, W. M., & Rice, C. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.01.004 · Cited by 410
Ferre, E. M. N., Rose, S. R., Rosenzweig, S. D., Burbelo, P. D., Romito, K. R., Niemela, J. E., Rosen, L. B., Break, T. J., Gu, W., Hunsberger, S., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88782 · Cited by 310
Self-citationAIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies
Meyer, S., Woodward, M., Hertel, C., Vlaicu, P., Haque, Y., Kärner, J., Macagno, A., Onuoha, S. C., Fishman, D., Peterson, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.024 · Cited by 292
Self-citationOftedal, B. E., Hellesen, A., Erichsen, M. M., Bratland, E., Vardi, A., Perheentupa, J., Kemp, E. H., Fiskerstrand, T., Viken, M. K., Weetman, A. P., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.021 · Cited by 286
Self-citationGlobal absence and targeting of protective immune states in severe COVID-19
Combes, A. J., Courau, T., Kuhn, N. F., Hu, K. H., Ray, A., Chen, W. S., Chew, N. W., Cleary, S. J., Kushnoor, D., Reeder, G. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03234-7 · Cited by 256
Bastard, P., Michailidis, E., Hoffmann, H.-H., Chbihi, M., Le Voyer, T., Rosain, J., Philippot, Q., Seeleuthner, Y., Gervais, A., Materna, M., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202486 · Cited by 247
Self-citationHuman IFNAR2 deficiency: Lessons for antiviral immunity
Duncan, C. J. A., Mohamad, S. M. B., Young, D. F., Skelton, A. J., Leahy, T. R., Munday, D. C., Butler, K. M., Morfopoulou, S., Brown, J. R., Hubank, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4227 · Cited by 237
Hernandez, N., Bucciol, G., Moens, L., Le Pen, J., Shahrooei, M., Goudouris, E., Shirkani, A., Changi-Ashtiani, M., Rokni-Zadeh, H., Sayar, E. H., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182295 · Cited by 179
Self-citationAberrant type 1 immunity drives susceptibility to mucosal fungal infections.
Break, T. J., Oikonomou, V., Dutzan, N., Desai, J. V., Swidergall, M., Freiwald, T., Chauss, D., Harrison, O. J., Alejo, J., Williams, D. W., et al. (2021) · Science · doi:10.1126/science.aay5731 · Cited by 175
Self-citationA single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Sanchez-Felipe, L., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Van Looveren, D., Arkalagud Javarappa, M. P., Boudewijns, R., Malengier-Devlies, B., Liesenborghs, L., et al. (2021) · Nature · doi:10.1038/s41586-020-3035-9 · Cited by 175
Constantine, G. M., & Lionakis, M. S. (2018) · Immunological Reviews · doi:10.1111/imr.12714 · Cited by 168
Self-citationA Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1
Bruserud, Ø., Oftedal, B. E., Landegren, N., Erichsen, M. M., Bratland, E., Lima, K., Jørgensen, A. P., Myhre, A. G., Svartberg, J., Fougner, K. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1821 · Cited by 159
Self-citationLife-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation
Zhang, Q., Bastard, P., Bolze, A., Jouanguy, E., Zhang, S., Cobat, A., Notarangelo, L. D., Su, H. C., Abel, L., & Casanova, J. (2020) · Med · doi:10.1016/j.medj.2020.12.001 · Cited by 156
Self-citationExpanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1
Orlova, E., Sozaeva, L., Kareva, M., Oftedal, B. E., Wolff, A. S. B., Breivik, L., Zakharova, E. Y., Ivanova, O. N., Kämpe, O., Dedov, I. I., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00139 · Cited by 140
Self-citationTroya, J., Bastard, P., Planas‐Serra, L., Ryan, P., Ruíz, M., de Carranza, M., Torres‐Macho, J., Martínez, A., Abel, L., Casanova, J., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01036-0 · Cited by 140
Self-citationKoning, R., Bastard, P., Casanova, J., Brouwer, M. C., van de Beek, D., with the Amsterdam U.M.C. COVID-19 Biobank Investigators, van Agtmael, M. A., Algera, A. G., Appelman, B., van Baarle, F., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06392-4 · Cited by 138
Self-citationHerpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency
Bastard, P., Manry, J., Chen, J., Rosain, J., Seeleuthner, Y., AbuZaitun, O., Lorenzo, L., Khan, T., Hasek, M. L., Hernandez, N., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139980 · Cited by 137
Self-citationViral infections in humans and mice with genetic deficiencies of the type I IFN response pathway
Meyts, I., & Casanova, J. (2021) · European Journal of Immunology · doi:10.1002/eji.202048793 · Cited by 120
Self-citationGenetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity
Duncan, C. J. A., Randall, R. E., & Hambleton, S. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.08.017 · Cited by 100
The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1)
Guo, C., Leung, P. S. C., Zhang, W., Ma, X., & Gershwin, M. E. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.012 · Cited by 90
Interferon deficiency can lead to severe COVID
Meffre, E., & Iwasaki, A. (2020) · Nature · doi:10.1038/d41586-020-03070-1 · Cited by 81
de Prost, N., Bastard, P., Arrestier, R., Fourati, S., Mahévas, M., Burrel, S., Dorgham, K., Gorochov, G., Tandjaoui-Lambiotte, Y., Azzaoui, I., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-00994-9 · Cited by 81
Self-citationFerré, E. M. N., Break, T. J., Burbelo, P. D., Allgäuer, M., Kleiner, D. E., Jin, D., Xu, Z., Folio, L. R., Mollura, D. J., Swamydas, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5597 · Cited by 77
Self-citationSevere COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis
Lemarquis, A. L., Campbell, T. M., Aranda‐Guillén, M., Hennings, V., Brodin, P., Kämpe, O., Blennow, K., Zetterberg, H., Wennerås, C., Eriksson, K., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.034 · Cited by 74
Self-citationIsaacs, A., Lindenmann, J.-M., & Valentine, R. C. (2015) · The Journal of Immunology · doi:10.1093/jimmunol/195.5.1921 · Cited by 69
Gresser, I. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.5.567 · Cited by 63
Bastard, P., Lévy, R., Henriquez, S., Bodemer, C., Szwebel, T., & Casanova, J. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01023-5 · Cited by 58
Self-citationBeccuti, G., Ghizzoni, L., Cambria, V., Codullo, V., Sacchi, P., Lovati, E., Mongodi, S., Iotti, G. A., & Mojoli, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01323-4 · Cited by 56
Self-citationSusceptibility to severe COVID-19
Beck, D. B., & Aksentijevich, I. A. (2020) · Science · doi:10.1126/science.abe7591 · Cited by 53
IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2
Lévy, R., Bastard, P., Lanternier, F., Lecuit, M., Zhang, S., & Casanova, J. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00933-0 · Cited by 51
Self-citationAnti-Interferon Auto-Antibodies in Autoimmune Polyendocrinopathy Syndrome Type 1
Levin, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030292 · Cited by 45
Central tolerance to self revealed by the autoimmune regulator
Chan, A. Y. K., & Anderson, M. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12960 · Cited by 45
Self-citationGothe, F., Hatton, C. F., Truong, L., Klimova, Z., Kanderová, V., Fejtková, M., Grainger, A., Bigley, V., Perthen, J. E., Mitra, D., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1790 · Cited by 37
van der Wijst, M. G. P., Vazquez, S. E., Hartoularos, G. C., Bastard, P., Grant, T., Bueno, R., Lee, D. S., Greenland, J. R., Sun, Y., Perez, R. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434529 · Cited by 34
Self-citationBreivik, L., Oftedal, B. E., Wolff, A. S. B., Bratland, E., Orlova, E., & Husebye, E. S. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.04.013 · Cited by 23
Self-citationNew immunodeficiency syndromes that help us understand the IFN-mediated antiviral immune response
Jing, H., & Su, H. C. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000827 · Cited by 21
Self-citation
Cited by
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
Bastard, P., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Manry, J., Michailidis, E., Hoffmann, H.-H., Eto, S., Garcia-Prat, M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4340 · Cited by 610
Self-citationX-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
Asano, T., Boisson, B., Onodi, F., Matuozzo, D., Moncada-Velez, M., Maglorius Renkilaraj, M. R. L., Zhang, P., Meertens, L., Bolze, A., Materna, M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4348 · Cited by 403
Self-citationHuman genetic and immunological determinants of critical COVID-19 pneumonia
Zhang, Q., Bastard, P., Effort, C. H. G., Karbuz, A., Gervais, A., Tayoun, A. A., Aiuti, A., Belot, A., Bolze, A., Gaudet, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04447-0 · Cited by 366
Self-citationImpaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Ziegler, C. G. K., Miao, V. N., Owings, A. H., Navia, A. W., Tang, Y., Bromley, J. D., Lotfy, P., Sloan, M., Laird, H., Williams, H. B., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.023 · Cited by 362
Metadata
- Authors
- Bastard, P., Orlova, E., Sozaeva, L., Lévy, R., James, A., Schmitt, M. M., Ochoa, S., Kareva, M., Rodina, Y., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Neehus, A.-L., Shaw, E., Migaud, M., Bizien, L., Ekwall, O., Berg, S., Beccuti, G., Ghizzoni, L., Thiriez, G., Pavot, A., Goujard, C., Frémond, M.-L., Carter, E., Rothenbuhler, A., Linglart, A., Mignot, B., Comte, A., Cheikh, N., Hermine, O., Breivik, L., Husebye, E. S., Humbert, S., Rohrlich, P., Coaquette, A., Vuoto, F., Faure, K., Mahlaoui, N., Kotnik, P., Battelino, T., Trebušak Podkrajšek, K., Kisand, K., Ferré, E. M. N., DiMaggio, T., Rosen, L. B., Burbelo, P. D., McIntyre, M., Kann, N. Y., Shcherbina, A., Pavlova, M., Kolodkina, A., Holland, S. M., Zhang, S.-Y., Crow, Y. J., Notarangelo, L. D., Su, H. C., Abel, L., Anderson, M. S., Jouanguy, E., Neven, B., Puel, A., Casanova, J.-L., & Lionakis, M. S.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-04-23
- Volume
- 218
- Issue
- 7
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W3155911740
- Cited by
- 299
- References
- 60
- FWCI
- 18.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.